Global Artificial Intelligence in Drug Discovery Market 2023-2029

https://marketpublishers.com/r/G262F55F326EEN.html

Date: February 2023
Pages: 82
Price: US$ 2,950.00 (Single User License)
ID: G262F55F326EEN

Abstracts

Artificial intelligence (AI) is increasingly utilised in drug discovery to tackle challenges that have hitherto been difficult to solve, such as predicting properties, designing molecules, and optimising synthetic routes. AI can recognize hit and lead compounds, and provide a quicker validation of the drug target and optimization of the drug structure design. The global artificial intelligence in drug discovery market was estimated at USD 991 million in 2022 and is expected to hit USD 4,673 million by 2029, registering a CAGR of 24.8% from 2023 to 2029 as per the latest market estimates.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global artificial intelligence in drug discovery market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors' approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the application, therapeutic space, end user, and region. The global market for artificial intelligence in drug discovery can be segmented by application: drug design, optimization and repurposing, preclinical and clinical testing, target identification, others. Among these, the drug design, optimization and repurposing segment was accounted for the highest revenue generator in 2022. Artificial intelligence in drug discovery market is further segmented by therapeutic space: cardiovascular diseases (CVD), infectious disease, metabolic diseases, neurological disorders, oncology, respiratory diseases, others. The oncology segment is estimated to account for the largest share of the global artificial intelligence in drug discovery market. Based on end user, the artificial intelligence in drug discovery market

is segmented into: academia and research institutes, contract research organizations (CROs), pharmaceutical and biotechnology companies. The pharmaceutical and biotechnology companies segment held the largest share of the global artificial intelligence in drug discovery market in 2022 and is anticipated to hold its share during the forecast period. On the basis of region, the artificial intelligence in drug discovery market also can be divided into: Asia-Pacific, Europe, North America, Middle East and Africa (MEA), South America. In 2022, North America made up the largest share of revenue generated by the artificial intelligence in drug discovery market.

Market Segmentation

By application: drug design, optimization and repurposing, preclinical and clinical testing, target identification, others

By therapeutic space: cardiovascular diseases (CVD), infectious disease, metabolic diseases, neurological disorders, oncology, respiratory diseases, others

By end user: academia and research institutes, contract research organizations (CROs), pharmaceutical and biotechnology companies

By region: Asia-Pacific, Europe, North America, Middle East and Africa (MEA), South America

The market research report covers the analysis of key stake holders of the global artificial intelligence in drug discovery market. Some of the leading players profiled in the report include Atomwise Inc., Accutar Biotechnology Inc., Ardigen S.A., BenevolentAI Limited, Berg LLC, Berkeley Lights, Inc., BioAge Labs, Inc., BioSymetrics Inc, Biovista Inc., C4X Discovery Holdings plc, Cloud Pharmaceuticals, Inc., Cyclica Inc., CytoReason Ltd., Deep Genomics Incorporated, DeepThink Health, Inc., Envisagenics, Inc., e-therapeutics plc, Euretos Services BV, Exscientia plc, GNS Healthcare Inc., Insilico Medicine Inc, Lantern Pharma Inc., NuMedii, Inc., Nuritas, Ltd., Owkin, Inc, Recursion Pharmaceuticals, Inc., Schrodinger, Inc., Symphony Innovation LLC, TARA Biosystems, Inc. (Valo Health, LLC), twoXAR, Inc. dba Aria Pharmaceuticals, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report

To analyze and forecast the market size of the global artificial intelligence in drug discovery market.

To classify and forecast the global artificial intelligence in drug discovery market based on application, therapeutic space, end user, region.

To identify drivers and challenges for the global artificial intelligence in drug discovery market.

To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global artificial intelligence in drug discovery market.

To identify and analyze the profile of leading players operating in the global artificial intelligence in drug discovery market.

Why Choose This Report

Gain a reliable outlook of the global artificial intelligence in drug discovery market forecasts from 2023 to 2029 across scenarios.

Identify growth segments for investment.

Stay ahead of competitors through company profiles and market data.

The market estimate for ease of analysis across scenarios in Excel format.

Strategy consulting and research support for three months.

Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY APPLICATION

Drug design, optimization and repurposing
Preclinical and clinical testing
Target identification
Others

PART 6. MARKET BREAKDOWN BY THERAPEUTIC SPACE

Cardiovascular diseases (CVD)
Infectious disease
Metabolic diseases
Neurological disorders
Oncology
Respiratory diseases
Others

PART 7. MARKET BREAKDOWN BY END USER

Academia and research institutes

Contract research organizations (CROs)

Pharmaceutical and biotechnology companies

PART 8. MARKET BREAKDOWN BY REGION

Asia-Pacific

Europe

North America

Middle East and Africa (MEA)

South America

PART 9. KEY COMPANIES

Atomwise Inc.

Accutar Biotechnology Inc.

Ardigen S.A.

BenevolentAI Limited

Berg LLC

Berkeley Lights, Inc.

BioAge Labs, Inc.

BioSymetrics Inc

Biovista Inc.

C4X Discovery Holdings plc

Cloud Pharmaceuticals, Inc.

Cyclica Inc.

CytoReason Ltd.

Deep Genomics Incorporated

DeepThink Health, Inc.

Envisagenics, Inc.

e-therapeutics plc

Euretos Services BV

Exscientia plc

GNS Healthcare Inc.

Insilico Medicine Inc

Lantern Pharma Inc.

NuMedii, Inc.

Nuritas, Ltd.

Owkin, Inc

Recursion Pharmaceuticals, Inc.

Schrodinger, Inc.

Symphony Innovation LLC

TARA Biosystems, Inc. (Valo Health, LLC)

twoXAR, Inc. dba Aria Pharmaceuticals

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

DISCLAIMER

I would like to order

Product name:	Global Artificial Intelligence in Drug Discovery Market 2023-2029
Product link:	https://marketpublishers.com/r/G262F55F326EEN.html
Price:	US$ 2,950.00 (Single User License / Electronic Delivery)
	If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
	info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G262F55F326EEN.html